Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the development of cytisinicline for nicotine dependence, has released its financial results for the fourth quarter and full year ended December 31, 2025. The company reported total operating expenses of $14.7 million for the fourth quarter and $54.9 million for the full year. The net loss for the same periods was $14.7 million and $54.7 million, respectively. As of December 31, 2025, Achieve had cash, cash equivalents, and marketable securities totaling $36.4 million.

In a significant development, Achieve announced a partnership with Adare Pharma Solutions for the manufacturing of cytisinicline, which is expected to enhance supply chain reliability and reduce costs associated with international importation. This partnership is seen as a strategic move to prepare for the anticipated U.S. commercial launch of cytisinicline in the first half of 2027.

The company also highlighted its progress towards regulatory approval, with the FDA accepting the New Drug Application (NDA) for cytisinicline, assigning a PDUFA target action date of June 20, 2026. Achieve's CEO, Rick Stewart, emphasized the commitment to providing a new solution for nicotine dependence, akin to the transformation seen in obesity treatments.

Achieve's operational execution has been bolstered by the completion of the ORCA-OL long-term exposure trial, which exceeded the required number of participants for FDA review. The company is also preparing for commercial readiness, including logistics and market access activities, in anticipation of the product launch. Achieve's strategic outlook remains focused on addressing the public health challenge of nicotine dependence, with ongoing scientific exchanges and data publication supporting the efficacy of cytisinicline.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.